Eupraxia Pharmaceuticals (EPRX) Net Equity Issued and Repurchased (2024)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Net Equity Issued and Repurchased of $22.9 million for Q1 2024.
Eupraxia Pharmaceuticals (EPRX) Net Equity Issued and Repurchased (2024) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Net Equity Issued and Repurchased for 1 consecutive years, with $22.9 million the latest figure, recorded in Q1 2024.
- In Q1 2024, Net Equity Issued and Repurchased changed N/A year-over-year to $22.9 million; the TTM figure through Dec 2024 stood at $22.9 million (changed N/A YoY), while the FY2025 annual figure was $73.9 million, up 223.33% from the prior year.
- Net Equity Issued and Repurchased steadied at $22.9 million in Q1 2024 per EPRX's latest filing.
- Across five years, Net Equity Issued and Repurchased topped out at $22.9 million in Q1 2024 and bottomed at $22.9 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 22.85 Mn |
| Mar 31, 2024 | 22.85 Mn |